Clinical efficacy and safety of ultrasound-guided injection with low-molecular-weight peptides from hydrolyzed collagen in patients with first carpometacarpal joint osteoarthritis - Report - MDSpire
Advertisement
Efficacy and Safety of Ultrasound-Guided Intra-Articular Injection of Low-Molecular-Weight Peptides from Hydrolyzed Collagen in Patients with Osteoarthritis of the First Carpometacarpal Joint
Efficacy and Safety of Ultrasound-Guided Intra-Articular Injection of Low-Molecular-Weight Peptides from Hydrolyzed Collagen in Patients with Osteoarthritis of the First Carpometacarpal Joint
Overview
This study evaluates the efficacy and safety of ultrasound-guided intra-articular injections of low-molecular-weight peptides derived from hydrolyzed collagen in patients with symptomatic osteoarthritis of the first carpometacarpal joint. The primary endpoint is the change in pain during activity after three months, with secondary outcomes including pain at rest and hand function.
Background
Osteoarthritis of the first carpometacarpal joint is a prevalent condition that leads to significant pain and functional impairment, particularly in middle-aged and older adults. Current treatment options include conservative measures and various injectable therapies.
Data Highlights
This study is a prospective single-arm interventional trial designed to assess the effects of low-molecular-weight peptides on pain and function in patients with CMC-1 OA over a follow-up period of up to six months.
Key Findings
The primary endpoint is the change in pain during activity after 3 months.
Secondary outcomes include pain at rest, hand disability, grip and key pinch strength, and patient-reported improvement.
The study will also evaluate treatment-related adverse events and ultrasonographic findings.
Baseline clinical and ultrasonographic patterns may be explored for their association with clinical and imaging responses.
Clinical Implications
The findings from this study may inform clinicians about the potential role of low-molecular-weight peptides as a treatment option for patients with symptomatic CMC-1 osteoarthritis.
Conclusion
The study aims to provide evidence on the efficacy and safety of a new injectable treatment for CMC-1 osteoarthritis. Further results will clarify its role.